[1] Angeli P, Gines P, Wong F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol,2015,62:968-974.
[2] Huelin P, Piano S, Solà E, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute on Chronic Liver Failure. Clin Gastroenterol Hepatol,2017;15:438-445.
[3] Arroyo V, Angeli P, Moreau R, et al. The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. J Hepatol, 2021,74:670-685.
[4] Piano S, Schmidt HH, Ariza X, et al. Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. Clin Gastroenterol Hepatol,2018,16:1792-1800.e3.
[5] Cullaro G, Park M, Lai JC. "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology,2018,68:1953-1960.
[6] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut,2015,64:531-537.
[7] Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology,2001,34:671-676.
[8] Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology,2007,45:223-229.
[9] Puthumana J, Ariza X, Belcher JM, et al. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2017,15:1003-1013 e1003.
[10] Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol,2012,8: 22-33.
[11] Zhang A, Sun H, Qiu S, et al. Metabolomics insights into pathophysiological mechanisms of nephrology. Int Urol Nephrol,2013, 46: 1025-1030.
[12] Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol,2021, 74:1117-1131.
[13] Silva RE, Baldim JL, Chagas-Paula DA, et al. Predictive metabolomic signatures of end-stage renal disease: A multivariate analysis of population-based data. Biochimie, 2018,152:14-30.
[14] Tankiewicz A, Pawlak D, Topczewska-Bruns J,et al. Kidney and liver kynurenine pathway enzymes in chronic renal failure. Adv Exp Med Biol,2003,527:409-414.
[15] Mor A, Kalaska B, Pawlak D. Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next? Int J Tryptophan Res,2020,13:1178.
[16] Bajaj J, Garcia-Tsao G, Reddy R, et al. Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients with Cirrhosis.Hepatology,2021,74:2699-2713.
[17] Poyan Mehr A, Tran MT, Ralto KM, et al. De novo NAD(+) biosynthetic impairment in acute kidney injury in humans. Nat Med,2018,24:1351-1359.
[18] Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol,2020,72:688-701.
[19] Claria J, Moreau R, Fenaille F, et al. Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. Hepatology,2019,69:1686-1701.
[20] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med,2021,384:818-828. |
